Kintara Therapeutics Liabilities 2024

Kintara Therapeutics Aktienanalyse

What does Kintara Therapeutics do?

Kintara Therapeutics Inc is a US-based biosciences company specializing in the development of cancer drugs and other clinical therapies. It was originally founded as DelMar Pharmaceuticals in 2008 before being renamed Kintara Therapeutics in 2019. The company focuses on developing drugs for the treatment of severe types of cancer such as glioblastoma, a particularly aggressive form of brain tumors. In addition, Kintara Therapeutics also develops clinical therapies for a broader range of indications, including breast cancer and lung cancer. Kintara Therapeutics has developed a proprietary technology platform called VAL-083, which is based on the effect of a chemical compound called dianhydrogalactitol (DAG). VAL-083 is being investigated as a potential treatment for various types of cancer, including those that have become resistant to other therapies. VAL-083 has received orphan drug designation status in the United States and Europe. This means that it is considered a promising new therapy for rare and serious diseases, allowing Kintara Therapeutics to have a faster approval process. In addition to the development of VAL-083, Kintara Therapeutics is also conducting a number of clinical trials on other drug candidates in its pipeline. This includes REM-001, a novel photoimmunotherapy drug for the treatment of cutaneous T-cell lymphomas. REM-001 is based on the use of light and a special type of antibodies to selectively destroy cancer cells. Another important area of business for Kintara Therapeutics is academic collaboration. The company works closely with academic institutions such as the Mayo Clinic, Duke University, and the University of California (San Francisco) to develop and test potential therapies. In addition, Kintara Therapeutics has also partnered with IQVIA, a leading provider of clinical study services, in order to achieve optimal results. In addition to the development and commercialization of cancer drugs, Kintara Therapeutics is also committed to responsible corporate governance. The company is dedicated to having a positive impact on patients, healthcare, and society as a whole through its products and business practices. Overall, Kintara Therapeutics has established a reputation as a reliable partner for the development of cancer therapies and other clinical therapies. The company has a strong portfolio of drug candidates and a broad base for collaborations to unleash its potential in healthcare. Kintara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Kintara Therapeutics's Liabilities

Kintara Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Kintara Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Kintara Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Kintara Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Kintara Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Kintara Therapeutics stock

What is the level of liabilities of Kintara Therapeutics this year?

Kintara Therapeutics has a debt balance of 2.44 M USD this year.

What were the liabilities of Kintara Therapeutics compared to the previous year?

The liabilities of Kintara Therapeutics have increased by -41.08% dropped compared to the previous year.

What are the consequences of high debt for investors of Kintara Therapeutics?

High liabilities can pose a risk for investors of Kintara Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Kintara Therapeutics?

Low liabilities mean that Kintara Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Kintara Therapeutics affect the company?

An increase in liabilities of Kintara Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Kintara Therapeutics affect the company?

A decrease in the liabilities of Kintara Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Kintara Therapeutics?

Some factors that can influence the liabilities of Kintara Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Kintara Therapeutics so important for investors?

The liabilities of Kintara Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Kintara Therapeutics take to modify the liabilities?

To change its liabilities, Kintara Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Kintara Therapeutics pay?

Over the past 12 months, Kintara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kintara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Kintara Therapeutics?

The current dividend yield of Kintara Therapeutics is .

When does Kintara Therapeutics pay dividends?

Kintara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kintara Therapeutics?

Kintara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Kintara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kintara Therapeutics located?

Kintara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kintara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kintara Therapeutics from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Kintara Therapeutics pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Kintara Therapeutics in the year 2023?

In the year 2023, Kintara Therapeutics distributed 0 USD as dividends.

In which currency does Kintara Therapeutics pay out the dividend?

The dividends of Kintara Therapeutics are distributed in USD.